Yogurt makers see US sales rise, driven by weight-loss drugs revolution

Ozempic revolution negatively impacts market value of food and drink companies while creating opportunities for those offering low-sugar, high-protein and nutrient-rich products

Major yogurt brands, including Danone, Fage, and Chobani, have experienced significant sales growth, with Fage seeing a 16% jump and Chobani's zero-sugar products surging by 55% in the first three months of the year, catering to consumers managing weight or under GLP-1 treatment.
The Ozempic Revolution has negatively impacted the market value of food and drink companies while creating opportunities for those offering low-sugar, high-protein, and nutrient-rich products. Nestle and Danone introduced specialized yogurt and frozen food products targeting users of obesity treatments.
1 View gallery
יוגורט. פרוביוטיקה
יוגורט. פרוביוטיקה
(Photo: Shutterstock)
The global market for GLP-1 drugs is predicted to reach $105 billion by 2030, with an estimated 31.5 million users in the U.S. by 2035, leading to a significant impact on the global economy and the food industry, prompting food executives to seek advice from pharmaceutical companies on adapting to the increasing use of appetite-suppressing medications.
Nestle and Danone stocks have seen fluctuations this year.
This article was written in collaboration with Generative AI news company Alchemiq
Sources: Donga, Quartz, Fortune, Axios.
<< Follow Ynetnews on Facebook | Twitter | Instagram >>
Comments
The commenter agrees to the privacy policy of Ynet News and agrees not to submit comments that violate the terms of use, including incitement, libel and expressions that exceed the accepted norms of freedom of speech.
""